← Back to headlines
Hemab and Seaport Make Trading Debuts After Upsized IPOs
Clinical-stage biotechs Hemab and Seaport have made their trading debuts, surging after pricing upsized initial public offerings that aimed to raise $550 million in proceeds.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
